Observational {{label}}

PRE-Symptomatic Studies in Amyotrophic Lateral Sclerosis


Overview

{{trial.Sponsor}} {{trial.Sponsor}}
{{route.Name}}
{{route.Name}}
Approved by FDA
Approved outside USA
Is a supplement

Details

Enrollment Criteria

{{m.Name}}
{{trial.ExternalId}} (First Published: {{trial.FirstPublishedDate|date}} on {{trial.SourceName}})
The goal of PRESS-ALS is to study the earliest manifestations of disease in people with early ALS in whom some areas of the body are not yet affected.

Inclusion Criteria
ALS group:
- Subject is a male or female, aged at least 18 years.
- Subject is affected with ALS (familial or sporadic).
- Subject has at least one limb in which there is no symptomatic upper and lower motor
neuron dysfunction.
- Subject is willing and able to comply with all study procedures.
- Subject agrees to provide signed and dated informed consent form.
Control group:
- Subject is a male or female, aged at least 18 years.
- Subject is not affected with ALS or an ALS-related disorder.
- Subject does not have a family history (i.e., at least 2 biological relatives) of ALS
or an ALS-related disorder.
- Subject is willing and able to comply with all study procedures.
- Subject agrees to provide signed and dated informed consent form.
Exclusion Criterion
• Any condition or situation which, in the PI's opinion, could confound the biomarker data
or may interfere significantly with the individual's participation and compliance with the
study protocol, including but not limited to neurological, psychological and/or medical
conditions (e.g., multiple sclerosis, neuropathy, myelopathy).

Locations
{{countryGroup}}
{{regionGroup}}
{{location.Facility}}
{{location.City !== '' ? location.City + ',' : ''}} {{location.RegionAbbreviation}} {{location.PostalCode}} {{location.Country}}
{{location.Facility !== '' ? location.Facility + ',' : ''}} {{location.City !== '' ? location.City + ',' : ''}} {{location.RegionAbbreviation}} {{location.PostalCode}} {{location.Country}}
Location Contact: {{location.Contact.Name}} {{location.Contact.Name}} Phone: {{location.Contact.Phone}}
Join the ALS Research Collaborative (ARC) Study Today!
Ready to make a difference in ALS research?
Join the ARC Study! Whether you're living with ALS or an asymptomatic gene carrier, your participation can help inform ALS research and lead to new treatments.
ALS Research Collaborative
Thank You to Our Sponsors
Mitsubishi Tanabe Pharma